Canadian Diabetes Association National Nutrition Committee technical review: Non-nutritive intense sweeteners in diabetes management

Canadian Journal of Diabetes

Volumn 28, Issue 4, 2004, Pages 385-399

  Gougeon, Réjeanne ^a,d   Spidel, Mark ^b   Lee, Kristy ^c   Field, Catherine J ^c  

^a MCGILL UNIVERSITY   (Canada)

^b Health and Social Services   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Acesulfame potassium (acesulfame K); Aspartame; Cyclamate; Non nutritive sweetener; Saccharin; Stevia; Sucralose; Tagatose; Thaumatin

Indexed keywords

ASPARTAME; CYCLAMATE SODIUM; FOOD ADDITIVE; GLUCOSE; LIPID; SACCHARIN; SUCRALOSE; SWEETENING AGENT; TAGATOSE;

APPETITE; BLOOD PRESSURE; BODY WEIGHT; CARBOHYDRATE INTAKE; DENTAL HEALTH; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HUNGER; KIDNEY FUNCTION; LACTATION; LIPID BLOOD LEVEL; LOW CALORY DIET; OBESITY; PRACTICE GUIDELINE; PREGNANCY; PREGNANT WOMAN; REVIEW; RISK BENEFIT ANALYSIS; SATIETY; WEIGHT CONTROL; WEIGHT REDUCTION;

EID: 28844444618     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Horwitz DL, Bauer-Nehrling JK. Can aspartame meet our expectations? J Am Diet Assoc. 1983;83:142-146.
2. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2003;27(suppl 2):S4-S6.
3. Garnier-Sagne I, Leblanc JC, Verger P. Calculation of the intake of three intense sweeteners in young insulin-dependent diabeties. Food Chem Toxicol. 2001;39:745-749.
4. Ilback NG, Alzin M, Jahrl S, et al. Estimated intake of the artificial sweeteners acesulfame-K, aspartame, cyclamate and saccharin in a group of Swedish diabetics. Food Addit Contam. 2003;20:99-114.
5. Toledo MC, Ioshi SH. Potential intake of intense sweeteners in Brazil. Food Addit Contam. 1995;12:799-808.
6. Leclercq C, Berardi D, Sorbillo MR, et al. Intake of saccharin, aspartame, acesulfame K and cyclamate in Italian teenagers: present levels and projections. Food Addit Contam. 1999;16:99-109.
7. Renwick AG. Intake of intense sweeteners. World Rev Nutr Diet. 1999;85:178-200.
8. Butchko HH, Stargel WW. Aspartame: scientific evaluation in the postmarketing period. Regul Toxicol Pharmacol. 2001;34:221-233.
9. Ranney RE, Oppermann JA, Muldoon E, McMahon FG. Comparative metabolism of aspartame in experimental animals and humans. J Toxicol Environ Health. 1976;2:441-451.
10. Dews PB. Summary report of an International Aspartame Workshop. Food Chem Toxicol. 1987;25:549-552.
11. Filer LJ Jr, Stegink LD. Aspartame metabolism in normal adults, phenylketonuricheterozygotes, and diabetic subjects. Diabetes Care. 1989;12:67-74.
12. Moller SE. Effect of aspartame and protein, administered in phenylalanine-equivalent doses, on plasma neutral amino acids, aspartate, insulin and glucose in man. Pharmacol Toxicol. 1991;68:408-412.
13. Wolf-Novak LC, Stegink LD, Brummel MC, et al. Aspartame ingestion with and without carbohydrate in phenylketonuric and normal subjects: effect on plasma concentrations of amino acids, glucose, and insulin. Metabolism. 1990;39:391-396.
14. Duffy VB, Anderson GH. Position of the American Dietetic Association: use of nutritive and nonnutritive sweeteners. J Am Diet Assoc. 1998;98:580-587.
15. Cohen S. Saccharin and urothelial proliferation: a threshold phenomenon [abstract]. FASEB J. 1992;6:A1594.
16. Renwick AG. Acceptable daily intake and the regulation of intense sweeteners. Food Addit Contam. 1990;7:463-475.
17. Food Safety Department, World Health Organization. Food Additives Must Be Used as Summers. Geneva, Switzerland: World Health Organization; 1994. Bulletin 6-10-1994.
18. Butchko HH, Stargel WW, Comer CP, et al. Aspartame: review of safety. Regul Toxicol Pharmacol. 2002;35:S1-S93.
19. Trefz F, de Sonneville L, Matthis P, et al. Neuropsychological and biochemical investigations in heterozygotes for phenylketonuria during ingestion of high dose aspartame (a sweetener containing phenylalanine). Hum Genet. 1994;93:369-374.
20. Mackey SA, Berlin CM Jr. Effect of dietary aspartame on plasma concentrations of phenylalanine and tyrosine in normal and homozygous phenylketonuric patients. Clin Pediatr (Phila). 1992;31:394-399.
21. Bradstock MK, Serdula MK, Marks JS, et al. Evaluation of reactions to food additives: the aspartame experience. Am J Clin Nutr. 1986;43:464-469.
22. Garriga MM, Berkebile C, Metcalfe DD. A combined single-blind, double-blind, placebo-controlled study to determine the reproducibility of hypersensitivity reactions to aspartame. J Allergy Clin Immunol. 1991;87:821-827.
23. Olney JW, Farber NB, Spitznagel E, ct al. Increasing brain tumor rates: is there a link to aspartame? J Neuropathol Exp Neurol. 1996;55:1115-1123.
24. Ross JA. Brain tumors and artificial sweeteners? A lesson on not getting soured on epidemiology. Med Pediatr Oncol. 1998;30:7-8.
25. Gurney JG, Pogoda JM, Holly EA, et al. Aspartame consumption in relation to childhood brain tumor risk: results from a case-control study. J Natl Cancer Inst. 1997;89:1072-1074.
26. Rowan AJ, Shaywitz BA, Tuchman L, et al. Aspartame and seizure susceptibility: results of a clinical study in reportedly sensitive individuals. Epilepsia. 1995;36:270-275.
27. Shaywitz BA, Sullivan CM, Anderson GM, et al. Aspartame, behavior, and cognitive function in children with attention deficit disorder. Pediatrics. 1994;93:70-75.
28. Shaywitz BA, Anderson GM, Novotny EJ, et al. Aspartame has no effect on seizures or epileptiform discharges in epileptic children. Ann Neurol. 1994;35:98-103.
29. Aspartame. Review of safety issues. Council on Scientific Affairs. JAMA. 1985;254:400-402.
30. Leon AS, Hunninghake DB, Bell C, et al. Safety of long-term large doses of aspartame. Arch Intern Med. 1989;149:2318-2324.
31. Stegink LD, Lindgren SD, Brummel MC, Stumbo PJ, Wolraich ML. Erythrocyte L-aspartyl-L-phenylalanine hydrolase activity and plasma phenylalanine and aspartate concentrations in children consuming diets high in aspartame. Am J Clin Nutr. 1995;62:1206-1211.
32. Schiffman SS, Buckley CE 3rd, Sampson HA, et al. Aspartame and susceptibility to headache. N Engl J Med. 1987;317:1181-1185.
33. Geha R, Buckley CE, Greenberger P, et al. Aspartame is no more likely than placebo to cause urticaria/angioedema: results of a multicenter, randomized, double-blind, placebo-controlled, crossover study. J Allergy Clin Immunol. 1993;92:513-520.
34. Roberts SS. Aspartame [response to letter to the editor], Diabetes forecast. 2001;54:14.
35. Renwick AG. The metabolism of intense sweeteners. Xenobiotica, 1986;16:1057-1071.
36. Evaluation of certain food additives and contaminants. Twenty-seventh Report of the Joint FAO/WHO Expert Committee on Food Additives. World Health Organ Tech Rep Ser. 1983;696:1-42.
37. Roberts A, Renwick AG, Sims J, et al. Sucralose metabolism and pharmacokinetics in man. Food Chem Toxicol. 2000;38 (suppl 2):S31-S41.
38. Baird IM, Shephard NW, Merritt RJ, et al. Repeated dose study of sucralose tolerance in human subjects. Food Chem Toxicol. 2000;38(suppl 2):S123-S129.
39. Grice HC, Goldsmith LA. Sucralose-an overview of the toxicity data. Food Chem Toxicol. 2000;38(suppl 2):S1-S6.
40. Sims J, Roberts A, Daniel JW, et al. The metabolic fate of sucralose in rats. Food Chem Toxicol. 2000;38(suppl 2):S115-S121.
41. John BA, Wood SG, Hawkins DR. The pharmacokinetics and metabolism of sucralose in the rabbit. Food Chem Toxicol. 2000;38(suppl 2):S111-S113.
42. John BA, Wood SG, Hawkins DR. The pharmacokinetics and metabolism of sucralose in the mouse. Food Chem Toxicol. 2000;38(suppl 2):S107-S110.
43. Wood SG, John BA, Hawkins DR. The pharmacokinetics and metabolism of sucralose in the dog. Food Chem Toxicol. 2000;38(suppl 2):S99-S106.
44. Mann SW, Yuschak MM, Amyes SJ, et al. A combined chronic toxicity/carcinogenicity study of sucralose in Sprague-Dawley rats. Food Chem Toxicol. 2000;38(suppl 2):S71-S89.
45. Mandel ID, Grotz VL. Dental considerations in sucralose use. J Clin Dent. 2002;13:116-118.
46. Livesey G, Brown JC. D-tagatose is a bulk sweetener with zero energy determined in rats. J Nutr. 1996;126:1601-1609.
47. Arnold DL, Krewski D, Munro IC. Saccharin: a toxicological and historical perspective. Toxicology. 1983;27:179-256.
48. Cohen SM. Saccharin: past, present, and future. J Am Diet Assoc. 1986;86:929-931.
49. Miller SA, Frattali VP. Saccharin. Diabetes Care. 1989;12:74-80.
50. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet. 1990;46:222-228.
51. Armstrong B, Lea AJ, Adelstein AM, et al. Cancer mortality and saccharin consumption in diabetics. Br J Prev Soc Med. 1976;30:151-157.
52. Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer. 1977;40:1246-1268.
53. Morrison AS, Buring JE. Artificial sweeteners and cancer of the lower urinary tract. N Engl J Med. 1980;302:537-541.
54. Walker AM, Dreyer NA, Friedlander E, et al. An independent analysis of the National Cancer Institute study on non-nutritive sweeteners and bladder cancer. Am J Public Health. 1982;72:376-381.
55. Oser BL. Highlights in the history of saccharin toxicology. Food Chem Toxicol. 1985;23:535-542.
56. Kojima S, Ichibagase H. Studies on synthetic sweetening agents. 8. Cyclohexylamine, a metabolite of sodium cyclamate. Chem Pharm Bull (Tokyo). 1966;14:971-974.
57. Buss NE, Renwick AG, Donaldson KM, et al. The metabolism of cyclamate to cyclohexylamine and its cardiovascular consequences in human volunteers. Toxicol Appl Pharmacol. 1992;115:199-210.
58. Higginbotham JD, Snodin DJ, Eaton KK, et al. Safety evaluation of thaumatin (Talin protein). Food Chem Toxicol. 1983;21:815-823.
59. Kinghorn AD, Kaneda N, Baek NI, et al. Noncariogenic intense natural sweeteners. Med Res Rev. 1998;18:347-360.
60. Johansen HN, Jensen BB. Recovery of energy as SCFA after microbial fermentation of D-tagatose [abstract]. Int J Obes. 1997;21(suppl 2):S50.
61. Raushel FM, Cleland WW. The substrate and anomeric specificity of fructokinase. J Biol Chem. 1973;248:8174-8177.
62. Saunders JP, Donner TW, Sadler JH, et al. Effects of acute and repeated oral doses of D-tagatose on plasma uric acid in normal and diabetic humans. Regul Toxicol Pharmacol. 1999;29: S57-S65.
63. Normen L, Laerke HN, Jensen BB, et al. Small-bowel absorption of D-tagatose and related effects on carbohydrate digestibility: an ileostomy study. Am J Clin Nutr. 2001;73:105-110.
64. Kruger CL, Whittaker MH, Frankos VH, et al. Developmental toxicity study of D-tagatose in rats. Regul Toxicol Pharmacol. 1999;29(2 Pt 2):S29-S35.
65. Barr RG, Pantel MS, Young SN, et al. The response of crying newborns to sucrose: is it a "sweetness" effect? Physiol Behav. 1999;66:409417.
66. Boesch C, Ith M, Jung B, et al. Effect of oral D-tagatose on liver volume and hepatic glycogen accumulation in healthy male volunteers. Regul Toxicol Pharmacol. 2001;33;257-267.
67. Bertelsen H, Jensen BB, Buemann B. D-tagatose - a novel low-calorie bulk sweetener with prebiotic properties. World Rev Nutr Diet. 1999;85:98-109.
68. Buemann B, Toubro S, Raben A, et al. Human tolerance to a single, high dose of D-tagatose. Regul Toxicol Pharmacol. 1999;29:S66-S70.
69. Levin GV. Tagatose, the new GRAS sweetener and health product. J Med Food. 2002;5:23-36.
70. Koyama E, Kitazawa K, Ohori Y, et al. In vitro metabolism of the glycosidic sweeteners, stevia mixture and enzymatically modified stevia in human intestinal microflora. Food Chem Toxicol. 2003;41:359-374.
71. Koyama E, Sakai N, Ohori Y, et al. Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, stevlol, in rats and humans. Food Chem Toxicol, 2003;41:875-883.
72. Das S, Das AK, Murphy RA, et al. Evaluation of the cariogenic potential of the intense natural sweeteners stevloside and rebaudioside A. Caries Res. 1992;26:363-366.
73. Cardoso VN, Barbosa MF, Muramoto E, Mesquita CH, Almeida MA. Pharmacokinetic studies of 1311-stevioside and its metabolites. Nucl Med Biol. 1996;23:97-100.
74. Toskulkao C, Chaturat L, Temcharoen P, et al. Acute toxicity of stevioside, a natural sweetener, and its metabolite, steviol, in several animal species. Drug Chem Toxicol. 1997;20:31-44.
75. Wasuntarawat C, Temcharoen P, Toskulkao C, et al. Developmental toxicity of steviol, a metabolite of stevioside, in the hamster. Drug Chem Toxicol. 1998;21:207-222.
76. Bertorelli AM, Czarnowski-Hill JV. Review of present and future use of nonnutritive sweeteners. Diabetes Educ. 1990;16:415-422.
77. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2003;27(suppl 2):S27-S31.
78. Horwitz DL, McLane M, Kobe P. Response to single dose of aspartame or saccharin by NIDDM patients. Diabetes Care. 1988;11:230-234.
79. Okuno G, Kawakami F, Tako H, et al. Glucose tolerance, blood lipid, insulin and glucagon concentration after single or continuous administration of aspartame in diabetics. Diabetes Res Clin Pract. 1986;2:23-27.
80. Stern SB, Bleicher SJ, Flores A, et al. Administration of aspartame in non-insulin-dependent diabetics. J Toxicol Environ Health. 1976;2:429-439.
81. Shigeta H, Yoshida T, Nakai M, et al. Effects of aspartame on diabetic rats and diabetic patients. J Nutr Sci Vitaminol (Tokyo). 1985;31:533-540.
82. Colagiuri S, Miller JJ, Edwards RA. Metabolic effects of adding sucrose and aspartame to the diet of subjects with non-insulin-dependent diabetes mellitus. Am J Clin Nutr. 1989;50:474-478.
83. Nehrling JK, Kobe P, McLane MP, et al. Aspartame use by persons with diabetes. Diabetes Care. 1985;8:415-417.
84. Singleton MJ, Heiser C, Jamesen K, et al. Sweetener augmentation of serum triacylglycerol during a fat challenge test in humans.J Am Colt Nutr. 1999;18:179-185.
85. Gupta V, Cochran C, Parker TF, et al. Effect of aspartame on plasma amino acid profiles of diabetic patients with chronic renal failure. Am J Clin Nutr. 1989;49:1302-1306.
86. Mezitis NH, Maggio CA, Koch P, et al. Glycemic effect of a single high oral dose of the novel sweetener sucralose in patients with diabetes. Diabetes Care. 1996;19:1004-1005.
87. Cooper PL, Wahlqvist ML, Simpson RW. Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabet Med. 1988;5:676-680.
88. Chantelau EA, Gosseringer G, Sonnenberg GE, et al. Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia. 1985;28:204-207.
89. Donner TW, Wither JF, Ostrowski D. D-tagatose, a novel hexose: acute effects on carbohydrate tolerance in subjects with and without type 2 diabetes. Diabetes Obis Metab. 1999;1:285-291.
90. Lewis GF, McNally C, Blackman JD, et al. Prior feeding alters the response to the 50-g glucose challenge test in pregnancy. The Staub-Traugott effect revisited. Diabetes Care. 1993;16:1551-1556.
91. Jeppesen PB, Gregersen S, Rolfsen SE, et al. Antihyperglycemic and blood pressure-reducing effects of stevioside in the diabetic Goto-Kakizaki rat. Metabolism. 2003;52:372-378.
92. Melis MS. Stevioside effect on renal function of normal and hypertensive rats. J Ethnopharmacol. 1992;36:213-217.
93. Liu JC, Kao PK, Chan P, et al. Mechanism of the antihypertensive effect of stevioside in anesthetized dogs. Pharmacology: 2003;67:14-20.
94. Jeppesen PB, Gregersen S, Poulsen CR, et al. Stevioside acts directly on pancreatic beta cells to secrete insulin: actions independent of cyclic adenosine monophosphate and adenosine triphosphate-sensitive K+-channel activity. Metabolism. 2000;49:208-214.
95. Chan P, Tomlinson B, Chen YJ, et al. A double-blind placebo-controlled study of the effectiveness and tolerability of oral stevioside in human hypertension. Br J Clin Pharmacol. 2000;50:215-220.
96. Katzmarzyk PT. The Canadian obesity epidemic: an historical perspective. Obes Res. 2002;10:666-674.
97. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 1999;282:1519-1522.
98. Richardson J F. The sugar intake of businessmen and its inverse relationship with relative weight. Br J Nutr. 1972;27:449-460.
99. Chen LN, Parham ES. College students' use of high-intensity sweeteners is not consistently associated with sugar consumption. J Am Diet Assoc. 1991;91:686-690.
100. Beaton GH, Tarasuk V, Anderson GH. Estimation of possible impact of non-caloric fat and carbohydrate substitutes on macronutrient intake in the human. Appetite. 1992;19:87-103.
101. Levitzki DA. Macronutrient intake and the control of body weight. In: Coulston AM, Rock CL, Monsen ER, eds. Nutrition in the Prevention and Treatment of Disease. San Diego, CA: Academic Press; 2001:pp 505.
102. Canty DJ, Chan MM. Effects of consumption of caloric vs noncaloric sweet drinks on indices of hunger and food consumption in normal adults. Am J Clin Nutr. 1991;53:1159-1164.
103. Blundell JE. Impact of nutrition on the pharmacology of appetite. Some conceptual issues. Ann N Y Acad Sci. 1989;575:163-169; discussion 169-170.
104. Drewnowski A, Massien C, Louis-Sylvestre J, et al. Comparing the effects of aspartame and sucrose on motivational ratings, taste preferences, and energy intakes in humans. Am J Clin Nutr. 1994;59:338-345.
105. Drewnowski A, Massien C, Louis-Sylvestre J, et al. The effects of aspartame versus sucrose on motivational ratings, taste preferences, and energy intakes in obese and lean women. Int J Obes Relat Metab Disord. 1994;18:570-578.
106. Black RM, Leiter LA, Anderson GH. Consuming aspartame with and without taste: differential effects on appetite and food intake of young adult males. Physiol Behav. 1993;53:459-466.
107. Holt SH, Sandona N, Brand-Miller JC. The effects of sugar-free vs sugar-rich beverages on feelings of fullness and subsequent food intake. Int J Food Sci Nutr. 2000;51:59-71.
108. Rolls BJ, Laster LJ, Summerfelt A. Hunger and food intake following consumption of low-calorie foods. Appetite. 1989;13:115-127.
109. Porikos KP, Hesser MF, van Itallie TB. Caloric regulation in normal-weight men maintained on a palatable diet of conventional foods. Physiol Behav. 1982;29:293-300.
110. Foltin RW, Fischman MW, Emurian CS, et al. Compensation for caloric dilution in humans given unrestricted access to food in a residential laboratory. Appetite. 1988;10:13-24.
111. Stellman SD, Garfinkel L. Artificial sweetener use and one-year weight change among women. Prev Med. 1986;15:195-202.
112. Tordoff MG, Alleva AM. Effect of drinking soda sweetened with aspartame or high-fructose corn syrup on food intake and body weight. Am J Clin Nutr. 1990;51:963-969.
113. Blackburn GL, Kanders BS, Lavin PT, et al. The effect of aspartame as part of a multidisciplinary weight-control program on short- and long-term control of body weight. Am J Clin Nutr. 1997;65:409-418.
114. Kanders BS, Lavin PT, Kowalchuk MB, et al. An evaluation of the effect of aspartame on weight loss. Appetite. 1988;11(supp11):73-84.
115. Raben A, Vasilaras TH, Moller AC, et al. Sucrose compared with artificial sweeteners: different effects on ad libitum food intake and body weight after 10 wk of supplementation in overweight subjects. Am J Clin Nutr. 2002;76:721-729.
116. Franz M. Is it safe to consume aspartame during pregnancy? A review. Nutrition update. Diabetes Educ. 1986;12:145-147.
117. Frey GH. Use of aspartame by apparently healthy children and adolescents. J Toxicol Environ Health. 1976;2:401-415.
118. Wolraich ML, Lindgren SD, Stumbo PJ, et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med. 1994;330:301-307.
119. Birch LL, McPhee L, Sullivan S. Children's food intake following drinks sweetened with sucrose or aspartame: time course effects. Physiol Behav. 1989;45:387-395.
120. London RS. Saccharin and aspartame. Are they safe to consume during pregnancy? J Reprod Med. 1988;33:17-21.
121. Sturtevant FM. Use of aspartame in pregnancy. Int J Fertil. 1985;30:85-87.
122. Stegink LD, Filer LJ Jr, Baker GL. Plasma, erythrocyte and human milk levels of free amino acids in lactating women administered aspartame or lactose. J Nutr. 1979;109:2173-2181.